首页> 美国卫生研究院文献>BMC Cancer >Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses

【2h】

Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses

机译：Pazopanib在晚期软组织肉瘤中的安全性和有效性：PALETTE（EORTC 62072）亚组分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundPALETTE is a phase 3 trial that demonstrated single-agent activity of pazopanib in advanced soft tissue sarcomas (aSTS). We performed retrospective subgroup analyses to explore potential relationships between patient characteristics, prior lines of therapy, dose intensity, and dose modifications on safety and efficacy of pazopanib in aSTS.

机译：背景PALETTE是一项3期试验，证明了帕唑帕尼在晚期软组织肉瘤（aSTS）中的单药活性。我们进行了回顾性亚组分析，以探讨患者特征，以前的治疗方案，剂量强度和剂量修改对aSTS中帕唑帕尼的安全性和有效性之间的潜在关系。

著录项

期刊名称 BMC Cancer
作者
Axel Le Cesne; Sebastian Bauer; George D. Demetri; Guangyang Han; Luca Dezzani; Qasim Ahmad; Jean-Yves Blay; Ian Judson; Patrick Schöffski; Massimo Aglietta; Peter Hohenberger; Hans Gelderblom;
展开▼
作者单位

展开▼
年(卷),期 2019(19),-1
年度 2019
页码 794
总页数 7
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
Pazopanib Advanced soft tissue sarcoma Progression-free survival PALETTE subgroup analysis;

机译：帕唑帕尼;晚期软组织肉瘤;无进展生存期;帕莱特亚组分析;

相似文献

外文文献
中文文献
专利

1. Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses [J] . Axel Le Cesne, Sebastian Bauer, George D. Demetri, BMC Cancer . 2019,第1期

机译：Pazopanib在晚期软组织肉瘤中的安全性和有效性：PALETTE（EORTC 62072）亚组分析
2. Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapya European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072) [J] . Coens Corneel, van der Graaf Winette T. A., Blay Jean-Yves, Cancer: A Journal of the American Cancer Society . 2015,第17期

机译：PALETTE得出的与健康有关的生活质量结果：帕唑帕尼与安慰剂治疗在先前化疗期间或之后疾病已进展的软组织肉瘤患者的一项随机，双盲，3期临床试验a欧洲研究和治疗软组织癌的组织组织和骨肉瘤组全球网络研究（EORTC 62072）
3. Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials [J] . Duffaud F., Sleijfer S., Litiere S., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2015,第17期

机译：高血压（HTN）作为Pazopanib治疗的晚期非脂肪细胞软组织肉瘤患者疗效的潜在生物标志物。基于欧洲研究和治疗癌症（EORTC）62043和62072试验的回顾性研究
4. Efficacy and Safety of Electrochemotherapy in the Treatment of Soft Tissue Sarcomas in Dogs [C] . Conference of the American College of Veterinary Internal Medicine (ACVIM) . 2017

机译：电化学疗法治疗狗软组织肉瘤的疗效和安全性
5. SAFETY AND DETERMINISTIC FAILURE ANALYSES IN HIGH-BETA D-D TOKAMAK REACTORS (FUSION SAFETY, ADVANCED FUSION, FUELS-SAFETY). [D] . SELCOW, ELIZABETH CAROL. 1984

机译：高倍率D-D托卡马克反应器的安全性和确定性故障分析（熔断安全，高级熔断，燃料安全）。
6. Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072 [O] . B. Kasper, S. Sleijfer, S. Litière, -1

机译：帕唑帕尼对晚期软组织肉瘤的长期反应者和幸存者：两项欧洲癌症研究和治疗组织（EORTC）临床试验62043和62072的亚分析
7. Association of pazopanib-induced toxicities with outcome of patients with advanced soft tissue sarcoma; a retrospective analysis based on the European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 clinical trials [O] . Melissa Vos, Stefan Sleijfer, Saskia Litière, 2019

机译：Pazopanib诱导的毒性与晚期软组织肉瘤患者的结果;基于欧洲癌症（EORTC）62043和62072临床试验的欧洲研究和治疗组织的回顾性分析

Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses

摘要

著录项

相似文献

相关主题

期刊订阅